Skip to main content
icon for FDA verschiebt BPC-157 um… in Kategorie 1?
Politik·Gesundheit

FDA verschiebt BPC-157 um… in Kategorie 1?

icon for FDA verschiebt BPC-157 um… in Kategorie 1?
Politik·Gesundheit

FDA verschiebt BPC-157 um… in Kategorie 1?

NEU
31. Aug. 2026
Polymarket

$2,649 Vol.

Polymarket

31. August 2026

$943 Vol.

13%

31. Dezember 2026

$1,706 Vol.

51%

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA removed BPC-157 from Category 2 (substances raising significant safety concerns for compounding) in April 2026 after nominations were withdrawn, following a February 2026 announcement by HHS regarding multiple peptides. On July 23, 2026, the Pharmacy Compounding Advisory Committee narrowly voted 8-6 (one abstention) to recommend BPC-157 for the 503A Bulks List, overriding agency staff opposition, alongside similar narrow approvals for related peptides. This advisory step supports potential reclassification to Category 1, which would permit licensed compounding pharmacies to prepare it under physician prescription, but does not equate to drug approval or immediate legal authority. Final FDA placement requires formal notice-and-comment rulemaking, a process typically spanning several additional months. BPC-157 remains unapproved for any medical use, with ongoing evaluation focused on immunogenicity risks and limited human data.

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.

A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.

Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.

A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.

The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volumen
$2,649
Enddatum
31. Dez. 2026
Markt eröffnet
Jun 22, 2026, 10:10 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA removed BPC-157 from Category 2 (substances raising significant safety concerns for compounding) in April 2026 after nominations were withdrawn, following a February 2026 announcement by HHS regarding multiple peptides. On July 23, 2026, the Pharmacy Compounding Advisory Committee narrowly voted 8-6 (one abstention) to recommend BPC-157 for the 503A Bulks List, overriding agency staff opposition, alongside similar narrow approvals for related peptides. This advisory step supports potential reclassification to Category 1, which would permit licensed compounding pharmacies to prepare it under physician prescription, but does not equate to drug approval or immediate legal authority. Final FDA placement requires formal notice-and-comment rulemaking, a process typically spanning several additional months. BPC-157 remains unapproved for any medical use, with ongoing evaluation focused on immunogenicity risks and limited human data.

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.

A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.

Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.

A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.

The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volumen
$2,649
Enddatum
31. Dez. 2026
Markt eröffnet
Jun 22, 2026, 10:10 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.

Verwandte

icon for Wird Trump Kyle Diamantas bis zum 31. Dezember als nächsten FDA-Kommissar ankündigen?

Wird Trump Kyle Diamantas bis zum 31. Dezember als nächsten FDA-Kommissar ankündigen?

28%
Ja
icon for Werden Seltzer mit 5 mg THC am 13. März 2027 legal sein?

Werden Seltzer mit 5 mg THC am 13. März 2027 legal sein?

28%
Ja
icon for Will Alibaba be removed from Chinese Military Companies list by June 30, 2027?

Will Alibaba be removed from Chinese Military Companies list by June 30, 2027?

47%

Vorsicht bei externen Links.

Häufig gestellte Fragen

„FDA verschiebt BPC-157 um… in Kategorie 1?" ist ein Prognosemarkt auf Polymarket mit 2 möglichen Ergebnissen, bei dem Händler Anteile auf Basis ihrer Einschätzung kaufen und verkaufen. Das aktuell führende Ergebnis ist „31. Dezember 2026" mit 51%, gefolgt von „31. August 2026" mit 13%. Die Preise spiegeln Echtzeit-Wahrscheinlichkeiten der Community wider. Ein Anteilspreis von 51¢ bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 51% zuweist. Diese Quoten ändern sich laufend, wenn Händler auf neue Entwicklungen reagieren. Anteile am richtigen Ergebnis können bei Marktauflösung für jeweils $1 eingelöst werden.

„FDA verschiebt BPC-157 um… in Kategorie 1?" ist ein neu erstellter Markt auf Polymarket, gestartet am Jun 22, 2026. Als früher Markt haben Sie die Gelegenheit, zu den ersten Händlern zu gehören, die die Quoten setzen und die ersten Preissignale des Marktes etablieren. Sie können diese Seite auch als Lesezeichen speichern, um Volumen und Handelsaktivität zu verfolgen, während der Markt an Fahrt gewinnt.

Um auf „FDA verschiebt BPC-157 um… in Kategorie 1?" zu handeln, durchsuchen Sie die 2 verfügbaren Ergebnisse auf dieser Seite. Jedes Ergebnis zeigt einen aktuellen Preis, der die implizierte Wahrscheinlichkeit des Marktes darstellt. Um eine Position einzunehmen, wählen Sie das Ergebnis, das Sie für am wahrscheinlichsten halten, wählen Sie „Ja" um dafür oder „Nein" um dagegen zu handeln, geben Sie Ihren Betrag ein und klicken Sie auf „Handeln". Liegt Ihr gewähltes Ergebnis bei Marktauflösung richtig, zahlen Ihre „Ja"-Anteile jeweils $1 aus. Liegt es falsch, zahlen sie $0. Sie können Ihre Anteile auch jederzeit vor der Auflösung verkaufen.

Der aktuelle Favorit für „FDA verschiebt BPC-157 um… in Kategorie 1?" ist „31. Dezember 2026" mit 51%, was bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 51% zuweist. Das nächstliegende Ergebnis ist „31. August 2026" mit 13%. Diese Quoten werden in Echtzeit aktualisiert, wenn Händler Anteile kaufen und verkaufen. Schauen Sie regelmäßig vorbei oder speichern Sie diese Seite als Lesezeichen.

Die Auflösungsregeln für „FDA verschiebt BPC-157 um… in Kategorie 1?" definieren genau, was passieren muss, damit jedes Ergebnis als Gewinner erklärt wird – einschließlich der offiziellen Datenquellen zur Bestimmung des Ergebnisses. Sie können die vollständigen Auflösungskriterien im Abschnitt „Regeln" auf dieser Seite über den Kommentaren einsehen. Wir empfehlen, die Regeln vor dem Handeln sorgfältig zu lesen, da sie die genauen Bedingungen, Sonderfälle und Quellen festlegen.